Shares of Esperion Therapeutics ESPR fell 2% in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share fell 21.83% over the past year to ($3.07), which beat the estimate of ($3.41).
Revenue of $3,833,000 rose by 290.72% year over year, which missed the estimate of $5,930,000.
Guidance
Esperion Sees FY 2020 R&D Expenses Between $135M And $145M, SG&A Expenses Between $200M And $210M
Conference Call Details
Date: Nov 02, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/d2vhtoax
Recent Stock Performance
52-week high: $76.98
52-week low: $24.82
Price action over last quarter: down 14.87%
Company Profile
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm has Business of researching, developing and commercializing therapies for the treatment of patients with the elevated LDL-C operating segment.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
